Resumen
IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.
| Idioma original | English (US) |
|---|---|
| Páginas (desde-hasta) | 1198-1204 |
| Número de páginas | 7 |
| Publicación | Current Opinion in Investigational Drugs |
| Volumen | 5 |
| N.º | 11 |
| Estado | Published - nov 2004 |
| Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery